Our COVID Vaccine Statement and other related resources for patients and our researchers and research staff are available on the COVID-19 Updates webpage.
Anuja Jhingran MD
Open to Accrual
To determine if adjuvant systemic chemotherapy following chemoradiation therapy will improve disease-free survival compared to chemoradiation therapy alone in patients with high-risk earlystage cervical carcinoma found to have positive nodes and/or positive parametria after a radical hysterectomy.
Available via the National Cancer Institute (NCI) Cancer Trials Support Unit (CTSU) website
Data for this trial is being collected via the NRG/RTOG Data Center.
Patients with clinical stage IA2, IB or IIA squamous, adenosquamous, or adenocarcinoma of the cervix who have any/all of the following high-risk features after surgery (this corresponds to surgical TNM staging of T1-T2, N1, M0):
Positive pelvic nodes
Positive para-aortic nodes- completely resected, PET/CT negative (PET only required if positive para-aortic nodes during surgery)
Dual Enrollment to RTOG 0724 and RTOG 1203
Patients are permitted to be enrolled onto both RTOG 0724 and RTOG 1203, however careful consideration must be made to the following:
We are a leading protocol organizations within the National Clinical Trials Network and we seek to improve the lives of cancer patients by conducting practice-changing, multi-institutional clinical and translational research. Learn More
NRG Oncology Foundation, Inc, is a nonprofit, tax-exempt foundation. Donations to NRG Oncology help us conduct this important mission, and are tax-deductible to the extent permitted by law.